Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1972 1
1975 4
1976 6
1977 8
1978 5
1979 5
1980 5
1981 12
1982 11
1983 17
1984 24
1985 16
1986 14
1987 29
1988 17
1989 27
1990 34
1991 26
1992 52
1993 33
1994 46
1995 45
1996 59
1997 59
1998 47
1999 52
2000 76
2001 85
2002 82
2003 93
2004 77
2005 88
2006 100
2007 113
2008 121
2009 147
2010 170
2011 169
2012 209
2013 239
2014 266
2015 207
2016 211
2017 212
2018 250
2019 235
2020 268
2021 291
2022 324
2023 299
2024 118

Text availability

Article attribute

Article type

Publication date

Search Results

4,300 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Recurrent Malignant Bladder Neoplasm"
Page 1
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma.
Powles T, Assaf ZJ, Davarpanah N, Banchereau R, Szabados BE, Yuen KC, Grivas P, Hussain M, Oudard S, Gschwend JE, Albers P, Castellano D, Nishiyama H, Daneshmand S, Sharma S, Zimmermann BG, Sethi H, Aleshin A, Perdicchio M, Zhang J, Shames DS, Degaonkar V, Shen X, Carter C, Bais C, Bellmunt J, Mariathasan S. Powles T, et al. Nature. 2021 Jul;595(7867):432-437. doi: 10.1038/s41586-021-03642-9. Epub 2021 Jun 16. Nature. 2021. PMID: 34135506 Clinical Trial.

Here we show that ctDNA testing at the start of therapy (cycle 1 day 1) identified 214 (37%) patients who were positive for ctDNA and who had poor prognosis (observation arm hazard ratio = 6.3 (95% confidence interval: 4.45-8.92); P < 0.0001). ...These data suggest that

…
Here we show that ctDNA testing at the start of therapy (cycle 1 day 1) identified 214 (37%) patients who were positive for ctDNA and who ha …
Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer.
Chen X, Zhang J, Ruan W, Huang M, Wang C, Wang H, Jiang Z, Wang S, Liu Z, Liu C, Tan W, Yang J, Chen J, Chen Z, Li X, Zhang X, Xu P, Chen L, Xie R, Zhou Q, Xu S, Irwin DL, Fan JB, Huang J, Lin T. Chen X, et al. J Clin Invest. 2020 Dec 1;130(12):6278-6289. doi: 10.1172/JCI139597. J Clin Invest. 2020. PMID: 32817589 Free PMC article. Clinical Trial.
BACKGROUNDCurrent methods for the detection and surveillance of bladder cancer (BCa) are often invasive and/or possess suboptimal sensitivity and specificity, especially in early-stage, minimal, and residual tumors.METHODSWe developed an efficient method, termed utMeMA, fo …
BACKGROUNDCurrent methods for the detection and surveillance of bladder cancer (BCa) are often invasive and/or possess suboptimal sen …
Identification of Differential Tumor Subtypes of T1 Bladder Cancer.
Robertson AG, Groeneveld CS, Jordan B, Lin X, McLaughlin KA, Das A, Fall LA, Fantini D, Taxter TJ, Mogil LS, Lindskrog SV, Dyrskjøt L, McConkey DJ, Svatek RS, de Reyniès A, Castro MAA, Meeks JJ. Robertson AG, et al. Eur Urol. 2020 Oct;78(4):533-537. doi: 10.1016/j.eururo.2020.06.048. Epub 2020 Jul 17. Eur Urol. 2020. PMID: 32684305
Stage T1 bladder cancers have the highest progression and recurrence rates of all non-muscle-invasive bladder cancers (NMIBCs). ...While most T1 tumors were classified as luminal papillary, the T1-TLum subtype had the highest median luminal papillary score …
Stage T1 bladder cancers have the highest progression and recurrence rates of all non-muscle-invasive bladder cancers ( …
BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer.
Rouanne M, Adam J, Radulescu C, Letourneur D, Bredel D, Mouraud S, Goubet AG, Leduc M, Chen N, Tan TZ, Signolle N, Bigorgne A, Dussiot M, Tselikas L, Susini S, Danlos FX, Schneider AK, Chabanon R, Vacher S, Bièche I, Lebret T, Allory Y, Soria JC, Arpaia N, Kroemer G, Kepp O, Thiery JP, Zitvogel L, Marabelle A. Rouanne M, et al. J Clin Invest. 2022 Jun 15;132(12):e145666. doi: 10.1172/JCI145666. J Clin Invest. 2022. PMID: 35503263 Free PMC article.
The mechanisms of resistance to such immunotherapy remain poorly understood. Here, using cancer cell lines, freshly resected human bladder tumors, and samples from cohorts of patients with bladder cancer before and after BCG therapy, we demonstrate 2 distinct patter …
The mechanisms of resistance to such immunotherapy remain poorly understood. Here, using cancer cell lines, freshly resected human bladde …
Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma.
Christensen E, Birkenkamp-Demtröder K, Sethi H, Shchegrova S, Salari R, Nordentoft I, Wu HT, Knudsen M, Lamy P, Lindskrog SV, Taber A, Balcioglu M, Vang S, Assaf Z, Sharma S, Tin AS, Srinivasan R, Hafez D, Reinert T, Navarro S, Olson A, Ram R, Dashner S, Rabinowitz M, Billings P, Sigurjonsson S, Andersen CL, Swenerton R, Aleshin A, Zimmermann B, Agerbæk M, Lin CJ, Jensen JB, Dyrskjøt L. Christensen E, et al. J Clin Oncol. 2019 Jun 20;37(18):1547-1557. doi: 10.1200/JCO.18.02052. Epub 2019 May 6. J Clin Oncol. 2019. PMID: 31059311
PURPOSE: Novel sensitive methods for early detection of relapse and for monitoring therapeutic efficacy may have a huge impact on risk stratification, treatment, and ultimately outcome for patients with bladder cancer. We addressed the prognostic and predictive impa …
PURPOSE: Novel sensitive methods for early detection of relapse and for monitoring therapeutic efficacy may have a huge impact on risk strat …
Young population bladder neoplasms.
Çivi Çetin K, Öner S, Erdoğan B, Simşek G, Sezer M. Çivi Çetin K, et al. Eur Rev Med Pharmacol Sci. 2023 Nov;27(21):10454-10461. doi: 10.26355/eurrev_202311_34320. Eur Rev Med Pharmacol Sci. 2023. PMID: 37975369 Free article.
There is no definitive information about the prognosis and clinical behavior of bladder cancer in young individuals. In our study, we aimed to investigate the prognosis and clinicopathological features of bladder tumors in patients under 40. ...All young patients ar …
There is no definitive information about the prognosis and clinical behavior of bladder cancer in young individuals. In our study, we …
A HER2-targeted Antibody-Drug Conjugate, RC48-ADC, Exerted Promising Antitumor Efficacy and Safety with Intravesical Instillation in Preclinical Models of Bladder Cancer.
Hong X, Chen X, Wang H, Xu Q, Xiao K, Zhang Y, Chi Z, Liu Y, Liu G, Li H, Fang J, Lin T, Zhang Y. Hong X, et al. Adv Sci (Weinh). 2023 Nov;10(32):e2302377. doi: 10.1002/advs.202302377. Epub 2023 Oct 12. Adv Sci (Weinh). 2023. PMID: 37824205 Free PMC article.
More than half of non-muscle-invasive bladder cancer (NMIBC) patients eventually relapse even if treated with surgery and BCG without optional bladder-preserving therapy. ...In this preclinical study, it is revealed that human epidermal growth factor receptor 2 (HER …
More than half of non-muscle-invasive bladder cancer (NMIBC) patients eventually relapse even if treated with surgery and BCG without …
Prediction for recurrent non-muscle invasive bladder cancer.
Li K, Raveendran A, Xie G, Zhang Y, Wu H, Huang Z, Jia Z, Yang J. Li K, et al. Cancer Biomark. 2023;38(3):275-285. doi: 10.3233/CBM-220373. Cancer Biomark. 2023. PMID: 37661872
Hence, it holds significant importance to predict the recurrence risk following treatment for individuals diagnosed with non-muscle invasive bladder cancer (NMIBC). ...This article provides an overview of the primary recurrence risk prediction t …
Hence, it holds significant importance to predict the recurrence risk following treatment for individuals diagnosed with non-m …
Novel endoscopic diagnosis for bladder cancer.
Lerner SP, Goh A. Lerner SP, et al. Cancer. 2015 Jan 15;121(2):169-78. doi: 10.1002/cncr.28905. Epub 2014 Aug 5. Cancer. 2015. PMID: 25132313 Free article. Review.
Prospective phase 3 clinical trials have demonstrated improved diagnostic ability, enhanced tumor resection, and a small but significant reduction in recurrence-free survival. Optical coherence tomography delineates subsurface microarchitecture information about bladder …
Prospective phase 3 clinical trials have demonstrated improved diagnostic ability, enhanced tumor resection, and a small but significant red …
Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature.
Kluth LA, Black PC, Bochner BH, Catto J, Lerner SP, Stenzl A, Sylvester R, Vickers AJ, Xylinas E, Shariat SF. Kluth LA, et al. Eur Urol. 2015 Aug;68(2):238-53. doi: 10.1016/j.eururo.2015.01.032. Epub 2015 Feb 21. Eur Urol. 2015. PMID: 25709027 Review.
CONTEXT: This review focuses on risk assessment and prediction tools for bladder cancer (BCa). OBJECTIVE: To review the current knowledge on risk assessment and prediction tools to enhance clinical decision making and counseling of patients with BCa. ...Speci …
CONTEXT: This review focuses on risk assessment and prediction tools for bladder cancer (BCa). OBJECTIVE: To review the curren …
4,300 results